ArticleEuropean journal of medical research2022

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Xi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.